DTC — Defence Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$48.16m
- CA$49.31m
Annual cashflow statement for Defence Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.673 | -2.86 | -7.34 | -6.76 | -13.2 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.493 | 0.606 | 0.371 | 0.558 | 6.23 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.048 | -0.036 | 0.928 | -1.36 | 2.58 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.133 | -2.29 | -6.04 | -7.66 | -4.29 |
| Capital Expenditures | -0.046 | — | — | -0.066 | -0.203 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.046 | — | — | -0.066 | -0.203 |
| Financing Cash Flow Items | -0.233 | -0.564 | 0 | -0.588 | -0.125 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.04 | 5.88 | 1.1 | 10 | 1.76 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.87 | 3.59 | -4.95 | 2.29 | -2.74 |